|
Gene: SLC25A51 |
Gene summary for SLC25A51 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC25A51 | Gene ID | 92014 |
Gene name | solute carrier family 25 member 51 | |
Gene Alias | CG7943 | |
Cytomap | 9p13.2-p13.1 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | Q9H1U9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
92014 | SLC25A51 | LZE4T | Human | Esophagus | ESCC | 4.16e-09 | 2.13e-01 | 0.0811 |
92014 | SLC25A51 | LZE7T | Human | Esophagus | ESCC | 6.13e-07 | 2.30e-01 | 0.0667 |
92014 | SLC25A51 | LZE24T | Human | Esophagus | ESCC | 8.32e-07 | 1.86e-01 | 0.0596 |
92014 | SLC25A51 | LZE6T | Human | Esophagus | ESCC | 1.62e-03 | 1.53e-01 | 0.0845 |
92014 | SLC25A51 | P2T-E | Human | Esophagus | ESCC | 4.98e-16 | 2.88e-01 | 0.1177 |
92014 | SLC25A51 | P4T-E | Human | Esophagus | ESCC | 3.86e-05 | 1.90e-01 | 0.1323 |
92014 | SLC25A51 | P5T-E | Human | Esophagus | ESCC | 1.20e-02 | 9.43e-02 | 0.1327 |
92014 | SLC25A51 | P8T-E | Human | Esophagus | ESCC | 9.81e-08 | 8.91e-02 | 0.0889 |
92014 | SLC25A51 | P9T-E | Human | Esophagus | ESCC | 2.11e-05 | 1.16e-01 | 0.1131 |
92014 | SLC25A51 | P10T-E | Human | Esophagus | ESCC | 1.05e-13 | 2.50e-01 | 0.116 |
92014 | SLC25A51 | P11T-E | Human | Esophagus | ESCC | 2.89e-10 | 4.09e-01 | 0.1426 |
92014 | SLC25A51 | P12T-E | Human | Esophagus | ESCC | 7.67e-06 | 1.22e-01 | 0.1122 |
92014 | SLC25A51 | P15T-E | Human | Esophagus | ESCC | 8.58e-10 | 2.28e-01 | 0.1149 |
92014 | SLC25A51 | P16T-E | Human | Esophagus | ESCC | 1.32e-06 | 1.42e-01 | 0.1153 |
92014 | SLC25A51 | P20T-E | Human | Esophagus | ESCC | 6.33e-07 | 1.27e-01 | 0.1124 |
92014 | SLC25A51 | P21T-E | Human | Esophagus | ESCC | 3.00e-12 | 2.28e-01 | 0.1617 |
92014 | SLC25A51 | P22T-E | Human | Esophagus | ESCC | 1.44e-07 | 1.46e-01 | 0.1236 |
92014 | SLC25A51 | P23T-E | Human | Esophagus | ESCC | 2.96e-02 | 8.42e-02 | 0.108 |
92014 | SLC25A51 | P24T-E | Human | Esophagus | ESCC | 6.29e-10 | 2.10e-01 | 0.1287 |
92014 | SLC25A51 | P26T-E | Human | Esophagus | ESCC | 2.81e-12 | 1.78e-01 | 0.1276 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002290412 | Liver | HCC | respiratory electron transport chain | 89/7958 | 114/18723 | 8.68e-15 | 5.73e-13 | 89 |
GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
GO:001964612 | Liver | HCC | aerobic electron transport chain | 67/7958 | 87/18723 | 5.43e-11 | 2.00e-09 | 67 |
GO:002290018 | Oral cavity | OSCC | electron transport chain | 126/7305 | 175/18723 | 6.65e-19 | 8.42e-17 | 126 |
GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
GO:000906018 | Oral cavity | OSCC | aerobic respiration | 133/7305 | 189/18723 | 1.79e-18 | 2.02e-16 | 133 |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:004533318 | Oral cavity | OSCC | cellular respiration | 153/7305 | 230/18723 | 2.07e-17 | 1.87e-15 | 153 |
GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
GO:002290418 | Oral cavity | OSCC | respiratory electron transport chain | 86/7305 | 114/18723 | 2.43e-15 | 1.63e-13 | 86 |
GO:001598018 | Oral cavity | OSCC | energy derivation by oxidation of organic compounds | 190/7305 | 318/18723 | 4.10e-14 | 2.26e-12 | 190 |
GO:001964618 | Oral cavity | OSCC | aerobic electron transport chain | 68/7305 | 87/18723 | 9.88e-14 | 5.17e-12 | 68 |
GO:004603420 | Oral cavity | OSCC | ATP metabolic process | 166/7305 | 277/18723 | 1.16e-12 | 5.12e-11 | 166 |
GO:000611919 | Oral cavity | OSCC | oxidative phosphorylation | 96/7305 | 141/18723 | 2.33e-12 | 9.75e-11 | 96 |
GO:199054218 | Oral cavity | OSCC | mitochondrial transmembrane transport | 56/7305 | 102/18723 | 8.06e-04 | 4.32e-03 | 56 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A51 | SNV | Missense_Mutation | novel | c.260N>A | p.Pro87Gln | p.P87Q | Q9H1U9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SLC25A51 | SNV | Missense_Mutation | rs747952145 | c.367G>A | p.Val123Met | p.V123M | Q9H1U9 | protein_coding | tolerated(0.34) | benign(0.015) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SLC25A51 | SNV | Missense_Mutation | rs370897815 | c.136N>A | p.Ala46Thr | p.A46T | Q9H1U9 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A51 | SNV | Missense_Mutation | novel | c.544N>T | p.Arg182Trp | p.R182W | Q9H1U9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A51 | SNV | Missense_Mutation | rs551338195 | c.478N>A | p.Ala160Thr | p.A160T | Q9H1U9 | protein_coding | tolerated(0.2) | benign(0.311) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A51 | SNV | Missense_Mutation | rs371433133 | c.712N>T | p.Arg238Cys | p.R238C | Q9H1U9 | protein_coding | tolerated(0.08) | benign(0.12) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC25A51 | SNV | Missense_Mutation | novel | c.439N>T | p.Asp147Tyr | p.D147Y | Q9H1U9 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC25A51 | insertion | Frame_Shift_Ins | novel | c.851_852insG | p.Ile285HisfsTer7 | p.I285Hfs*7 | Q9H1U9 | protein_coding | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SLC25A51 | insertion | Frame_Shift_Ins | novel | c.690dupT | p.Pro231SerfsTer3 | p.P231Sfs*3 | Q9H1U9 | protein_coding | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
SLC25A51 | SNV | Missense_Mutation | novel | c.602N>C | p.Leu201Pro | p.L201P | Q9H1U9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |